[go: up one dir, main page]

MA34643B1 - Composant comprenant du 2-méthylpropanethioate de s-[2-([[1-(2-éthylbutyl)-cyclohexyl]-carbonyl]amino)phényle] et de la croscarmellose sodique - Google Patents

Composant comprenant du 2-méthylpropanethioate de s-[2-([[1-(2-éthylbutyl)-cyclohexyl]-carbonyl]amino)phényle] et de la croscarmellose sodique

Info

Publication number
MA34643B1
MA34643B1 MA35868A MA35868A MA34643B1 MA 34643 B1 MA34643 B1 MA 34643B1 MA 35868 A MA35868 A MA 35868A MA 35868 A MA35868 A MA 35868A MA 34643 B1 MA34643 B1 MA 34643B1
Authority
MA
Morocco
Prior art keywords
methylpropanethioate
ethylbutyl
cyclohexyl
carbonyl
croscarmellosis
Prior art date
Application number
MA35868A
Other languages
English (en)
Inventor
Michaela Krabichler
Bernard Meyer
Carsten Winzenburg
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43759428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34643(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA34643B1 publication Critical patent/MA34643B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition contenant : a) du 2-méthylpropanethioate de S-[2-([[1-(2-éthylbutyl)cyclohexyl]carbonyl]
MA35868A 2010-11-04 2013-05-03 Composant comprenant du 2-méthylpropanethioate de s-[2-([[1-(2-éthylbutyl)-cyclohexyl]-carbonyl]amino)phényle] et de la croscarmellose sodique MA34643B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10190045 2010-11-04
PCT/EP2011/069087 WO2012059447A1 (fr) 2010-11-04 2011-10-31 Composant comprenant du 2-méthylpropanethioate de s-[2-([[1-(2-éthylbutyl)-cyclohexyl]-carbonyl]amino)phényle] et de la croscarmellose sodique

Publications (1)

Publication Number Publication Date
MA34643B1 true MA34643B1 (fr) 2013-11-02

Family

ID=43759428

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35868A MA34643B1 (fr) 2010-11-04 2013-05-03 Composant comprenant du 2-méthylpropanethioate de s-[2-([[1-(2-éthylbutyl)-cyclohexyl]-carbonyl]amino)phényle] et de la croscarmellose sodique

Country Status (25)

Country Link
US (1) US9107836B2 (fr)
EP (1) EP2635263B1 (fr)
JP (1) JP5676005B2 (fr)
KR (1) KR101579659B1 (fr)
CN (2) CN103200935A (fr)
AR (1) AR083693A1 (fr)
BR (1) BR112013010704B8 (fr)
CA (1) CA2815280C (fr)
CL (1) CL2013001164A1 (fr)
CR (1) CR20130181A (fr)
EA (1) EA025649B1 (fr)
EC (1) ECSP13012603A (fr)
ES (1) ES2553279T3 (fr)
IL (1) IL225780B (fr)
MA (1) MA34643B1 (fr)
MX (1) MX345650B (fr)
MY (1) MY164729A (fr)
NZ (1) NZ609529A (fr)
PE (1) PE20140018A1 (fr)
PH (1) PH12013500864A1 (fr)
SG (1) SG190025A1 (fr)
TW (1) TWI507192B (fr)
UA (1) UA110117C2 (fr)
WO (1) WO2012059447A1 (fr)
ZA (1) ZA201302954B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3037089T (pt) 2009-02-10 2020-03-04 Amarin Pharmaceuticals Ie Ltd Ester etílico de ácido eicosapentaenoico para tratamento de hipertrigliceridemia
EP3404115A1 (fr) 2013-03-27 2018-11-21 F. Hoffmann-La Roche AG Marqueurs génétiques permettant de prédire la réactivité à une thérapie
JP5871984B2 (ja) * 2013-04-15 2016-03-01 株式会社三和化学研究所 オルメサルタンメドキソミルを含有する医薬組成物
RU2016127357A (ru) 2013-12-19 2018-01-24 Ф. Хоффманн-Ля Рош Аг Модулятор сетр для применения в лечении заболеваний глаз
MX384679B (es) 2014-07-30 2025-03-14 Hoffmann La Roche Marcadores genéticos para predecir la reactividad a terapia con agente que eleva la lipoproteína de alta densidad (hdl) o que imita la lipoproteína de alta densidad (hdl).
CN104434913A (zh) * 2014-12-20 2015-03-25 长沙佰顺生物科技有限公司 一种安塞曲匹药物组合物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Cetp活性阻害剤として有効な化合物
US7208465B2 (en) * 2000-11-03 2007-04-24 The Procter & Gamble Company Methods and compositions for improved fragrancing of a surface
KR20050088190A (ko) * 2002-12-20 2005-09-02 화이자 프로덕츠 인코포레이티드 콜레스테릴 에스터 전달 단백질 억제제 및 hmg-coa환원 효소 억제제를 포함하는 투약 형태
ATE534381T1 (de) * 2003-03-17 2011-12-15 Japan Tobacco Inc Pharmazeutische cetp-inhibitor-zusammensetzungen
US7276536B2 (en) 2003-03-17 2007-10-02 Japan Tobacco Inc. Method for increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino) phenyl] 2-methylpropanethioate
BRPI0413363A (pt) * 2003-08-04 2006-10-10 Pfizer Prod Inc formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
EP1845947B1 (fr) * 2005-01-28 2008-12-31 Pfizer Products Inc. Liants microporeux a desintegration rapide et procédé pour le fabriquer
US7435849B2 (en) 2005-10-31 2008-10-14 Hoffmann-La Roche Inc. Process for the production of acid chlorides
EP1935867A1 (fr) 2006-12-20 2008-06-25 F. Hoffmann-La Roche Ag Procédé de préparation de l'acide 1-(2-éthyl-butyl)-cyclohexanecarboxylique
WO2010066593A1 (fr) * 2008-12-08 2010-06-17 F. Hoffmann-La Roche Ag Administration combinée de médicaments
US20110004011A1 (en) 2009-07-01 2011-01-06 Declan Costello Novel process

Also Published As

Publication number Publication date
MX345650B (es) 2017-02-09
ES2553279T3 (es) 2015-12-07
EP2635263B1 (fr) 2015-09-23
TW201300104A (zh) 2013-01-01
SG190025A1 (en) 2013-06-28
AU2011325235A1 (en) 2013-05-02
CR20130181A (es) 2013-05-29
BR112013010704B8 (pt) 2021-11-09
IL225780A0 (en) 2013-06-27
ZA201302954B (en) 2016-01-27
NZ609529A (en) 2015-06-26
PE20140018A1 (es) 2014-01-31
KR101579659B1 (ko) 2015-12-22
AR083693A1 (es) 2013-03-13
KR20130083922A (ko) 2013-07-23
CA2815280A1 (fr) 2012-05-10
BR112013010704A2 (pt) 2016-08-09
EP2635263A1 (fr) 2013-09-11
WO2012059447A1 (fr) 2012-05-10
EA201390622A1 (ru) 2013-10-30
AU2011325235B2 (en) 2016-01-21
IL225780B (en) 2018-10-31
JP2013541572A (ja) 2013-11-14
UA110117C2 (uk) 2015-11-25
JP5676005B2 (ja) 2015-02-25
BR112013010704B1 (pt) 2021-06-29
EA025649B1 (ru) 2017-01-30
PH12013500864A1 (en) 2017-08-23
US20120115946A1 (en) 2012-05-10
CN103200935A (zh) 2013-07-10
CN105833283A (zh) 2016-08-10
MY164729A (en) 2018-01-30
CA2815280C (fr) 2016-08-09
TWI507192B (zh) 2015-11-11
US9107836B2 (en) 2015-08-18
MX2013004584A (es) 2013-05-17
ECSP13012603A (es) 2013-07-31
AU2011325235A8 (en) 2016-02-04
CL2013001164A1 (es) 2013-12-27

Similar Documents

Publication Publication Date Title
MA34643B1 (fr) Composant comprenant du 2-méthylpropanethioate de s-[2-([[1-(2-éthylbutyl)-cyclohexyl]-carbonyl]amino)phényle] et de la croscarmellose sodique
CR10269A (es) "nuevo derivado de cumarina que tiene actividad antitumoral"
PH12014502397A1 (en) Pesticidal compositions and processes related thereto
MA35280B1 (fr) Inhibiteurs de l'activation des lymphocytes t
MA35402B1 (fr) Compositions pesticides et procédés associés
CO6680675A2 (es) Tidiazoles substituidos y composiciones pesticidas que los contienen
EP2264100A4 (fr) Composition d'élastomère contenant du fluor réticulé par peroxyde
DE112009002168A5 (de) Auslieferung und Management von virtuellen Containern
ATE515497T1 (de) Insektizide n-substituierte (6-haloalkylpyridin-3-yl)alkyl-sulfoximine
NZ716421A (en) Drug for treatment of nonalcoholic fatty liver disease
ITMO20060222A1 (it) Pacchetto di medicazione antiemorragico
EP2074745A4 (fr) Identification de source active pour conférences téléphoniques
EP2789245A4 (fr) Composition d'émulsion et composition la contenant
DE602006019234D1 (de) Augenoptische einrichtungen für aufrechterhaltene abgabe aktiver zusammensetzungen
FR2930081B1 (fr) Garniture d'etancheite pour connecteur
BR112014002758A2 (pt) composições para cuidados pessoais contendo zinco piritiona submetido à secagem
EP3995489A3 (fr) Composés à base de disulfure pour l'administration d'agents pharmaceutiques
BRPI0716765A2 (pt) mÉtodos e composiÇÕes para administrar agentes hipoglicÊmicos de longa duraÇço
EP2210601A4 (fr) Agent antifatigue comprenant une composition d'acides aminés
FR2968032B1 (fr) Ensemble d'etancheite pour turbomachine
BRPI0815303A2 (pt) "componenete elástico para uma vestimenta com vedação melhorada"
EP1987825A4 (fr) Composition pharmaceutique comprenant du phosphate d'oseltamivir
EP2621942A4 (fr) Agents fournissant des témoins et des étalons pour des tests d'immunoprécipitation
EP2070982A4 (fr) Composition élastomère contenant du fluor
FR2950232B1 (fr) Ensemble de conditionnement et d'application cosmetique pour compositions rheofluidifiantes